catalyst

Visibility is the theme this month, with brokers backing stocks that have clear catalysts for growth and re-ratings.

L1 Capital's James Hawkins recently conducted a webinar discussing the Catalyst Fund. Here we summarise the highlights of the session.

LTR Pharma is a clinical-stage pharmaceutical company, commercialising a world first in erectile dysfunction, Spontan, a PDE5 nasal spray.

Activist investing continues to rise in prominence in Australia. In this wire James Hawkins of L1 Capital shares his insights on the space.

In this episode, Elston's Justin Woerner and LSN Capital's Nick Sladen analyse five stocks with possible share price-moving catalysts.

Leveraging expertise for expansive growth

Game changing catalysts typically drive share price re-ratings for companies. So which companies have major developments on the horizon?

In this episode, PM Capital's Paul Moore and Antipodes' Jacob Mitchell analyse five stocks making waves on the global stage this year.

Last year, L1 Capital invested in a little-known fuel retailer out of New Zealand. At the time, the team thought the company was undervalued and boasted high-quality...

It was Nobel prize laureate Harry Markowitz who famously posited that the "only free lunch in investing is diversification". By this, he meant that diversification...